Decreased serum levels of the inflammaging marker miR-146a are associated with clinical non-response to tocilizumab in COVID-19 patients
Jacopo Sabbatinelli, Angelica Giuliani, Giulia Matacchione, Silvia Latini, Noemi Laprovitera, Giovanni Pomponio, Alessia Ferrarini, Silvia Svegliati Baroni, Marianna Pavani, Marco Moretti, Armando Gabrielli, Antonio Domenico Procopio, Manuela Ferracin, Massimiliano Bonafè, Fabiola Olivieri
Topics & Concepts
TocilizumabMedicineCoronavirus disease 2019 (COVID-19)Internal medicineBiomarkerAdverse effectPneumoniaClinical significanceGastroenterologyImmunologyRheumatoid arthritisDiseaseInfectious disease (medical specialty)BiochemistryChemistryCOVID-19 Clinical Research StudiesExtracellular vesicles in diseaseInflammasome and immune disorders